Notice of Clarification: Research Strategy page limit for PAR-18-549, Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)

Notice Number: NOT-NS-19-008

Key Dates
Release Date:October 15, 2018

Related Announcements
PAR-18-550

 PAR-18-664

 PAR-18-548

 PAR-18-549

RFA-NS-18-046

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

This Notice is to clarify the Research Strategy page limit for PAR-18-549, Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional).

The Research Strategy section page limit has been increased from 12 to 20 pages to allow additional space for materials that are disallowed in the Appendix. Figures, tables, graphs, diagrams, data, and charts that are necessary to support the proposal should be included in the Research Strategy section, as these are not appropriate for the Appendix. Do not use the Appendix to circumvent page limits. For Allowable Appendix Materials, follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide. Allowable Appendix Materials are restricted. Please see the NIH Guide Notice on Allowable Appendix Materials and the FAQs on the NIH Appendix Policy for more information. If an application is submitted with disallowed materials in the Appendix it will be withdrawn for noncompliance.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Mary Ann Pelleymounter, PhD 
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779 
Email:  mary.pelleymounter@nih.gov